Drug Trial Radar · NCT00171821
A Study Assessing the Efficacy and Safety of Deferasirox in Patients With Transfusion-dependent Iron Overload
Last checked: Nov 20, 2026Latest source record: Feb 11, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,784
Actual
Start
Apr 2005
Primary completion
May 2009
Study completion Jul 2010
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study uses a single arm, multi-center, open-label trial design. The study will assess the efficacy and safety of 52 weeks of treatment with deferasirox (ICL670) in patients with evidence of transfusion induced iron overload.
Conditions
- Transfusion-dependent Iron Overload
Interventions
DeferasiroxDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate if fixed starting doses of ICL670, based on transfusion history and subsequent dose titration can provide clinically acceptable chelation as measured by serum ferritinTime frame: at baseline and at 52 weeks
Locations
97 sites in 23 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Adelaide, Australia
Novartis Investigative Site
Camperdown, Australia
Novartis Investigative Site
Clayton, Australia
Novartis Investigative Site
Melbourne, Australia
Novartis Investigative Site
Perth, Australia
Novartis Investigative Site
South Brisbane, Australia
Novartis Investigative Site
Westmead, Australia
Novartis Investigative Site
Graz, Austria
Novartis Investigative Site
Linz, Austria
Novartis Investigative Site
Vienna, Austria
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Ghent, Belgium
Novartis Investigative Site
Godinne, Belgium
Novartis Investigative Site
La Louvière, Belgium
Novartis Investigative Site
Leuven, Belgium
Novartis Investigative Site
Guangzhou, China
Novartis Investigative Site
Nanjing, China
Novartis Investigative Site
Shanghai, China
Novartis Investigative Site
Aarhus, Denmark
Novartis Investigative Site
Copenhagen, Denmark
Novartis Investigative Site
Herlev, Denmark
Novartis Investigative Site
Hillerød, Denmark
Novartis Investigative Site
Cairo, Egypt
Novartis Investigative Site
Angers, France
Novartis Investigative Site
Avignon, France
Novartis Investigative Site
Bobigny, France
Novartis Investigative Site
Créteil, France
Novartis Investigative Site
Lille, France
Novartis Investigative Site
Lyon, France
Novartis Investigative Site
Nice, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Pessac, France
Novartis Investigative Site
Rennes, France
Novartis Investigative Site
Toulouse, France
Novartis Investigative Site
Vandœuvre-lès-Nancy, France
Novartis Investigative Site
Augsburg, Germany
Novartis Investigative Site
Braunschweig, Germany
Novartis Investigative Site
Dresden, Germany
Novartis Investigative Site
Düsseldorf, Germany
Novartis Investigative Site
Frankfurt, Germany
Showing 40 of 97 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.